Halberd (OTCMKTS:HALB) vs. Compugen (NASDAQ:CGEN) Head to Head Contrast

Halberd (OTCMKTS:HALB) and Compugen (NASDAQ:CGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Institutional and Insider Ownership

12.2% of Compugen shares are held by institutional investors. 75.6% of Halberd shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Halberd and Compugen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halberd	N/A	N/A	N/A
Compugen	N/A	-16.10%	-9.23%

Valuation and Earnings

This table compares Halberd and Compugen”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halberd	N/A	N/A	N/A	($0.01)	-0.60
Compugen	$42.72 million	3.68	-$18.75 million	($0.19)	-9.26

Halberd has higher earnings, but lower revenue than Compugen. Compugen is trading at a lower price-to-earnings ratio than Halberd, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Halberd and Compugen, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halberd	0	0	0	0	N/A
Compugen	0	0	2	0	3.00

Compugen has a consensus price target of $4.00, suggesting a potential upside of 127.27%. Given Compugen’s higher probable upside, analysts plainly believe Compugen is more favorable than Halberd.

Summary

Halberd beats Compugen on 5 of the 9 factors compared between the two stocks.

About Halberd

Halberd Corporation, a biotech company, develops treatments for neurodegenerative diseases. It offers treatments for post traumatic stress disorder/chronic traumatic encephalopathy, Alzheimer's and Parkinson's disease, cancer, blood-borne, and cerebrospinal fluid related diseases. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.